CTOs on the Move

Medicare Rights Center

www.medicarerights.org

 
Medicare Rights Center is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Bournewood Hospital

Bournewood Hospital is a full-service, independent psychiatric hospital licensed for 90 beds, which has been in continuous operation as a psychiatric hospital on twelve acres in South Brookline since 1895

Imaging Healthcare Specialists

Imaging Healthcare Specialists is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caldera Care

Caldera Care is a premiere provider of skilled nursing care in the Pacific Northwest.

Integrity Home Health Care Services

Integrity Home Health Care Services is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.